Elevance Health Reports Third Quarter 2026 Results; Raises Full-Year Guidance
Elevance Health reported Q3 2026 results ahead of expectations, with operating revenue of $50.4 billion (up 0.7% YoY), GAAP diluted EPS of $6.27, and adjusted diluted EPS of $6.99, up 15.9% year-over-year. The company raised FY 2026 guidance to at least $22.00 GAAP EPS and at least $29.00 adjusted EPS, lifted operating cash flow guidance to at least $6.5 billion, and pointed to at least 12% adjusted EPS growth in 2027 off a baseline of at least $26.75.
Key figures
- Eps
- 6.27
- Revenue
- 50440000000
- Guidance
- FY 2026 GAAP diluted EPS raised to at least $22.00; adjusted diluted EPS raised to at least $29.00; FY 2026 operating cash flow raised to at least $6.5 billion; 2027 adjusted EPS growth of at least 12% off a baseline of at least $26.75
- Revenue Yoy
- 0.7%
- Q3 buyback
- 0.8 million shares for $330 million at $398.75 average
- Operating gain
- 1269000000
- Adjusted eps yoy
- 15.9%
- Operating margin
- 2.5%
- Medical membership
- 44882000
- Benefit expense ratio
- 90.6%
- Days in claims payable
- 44.9
- Operating cash flow q3
- 1300000000
- Adjusted diluted eps q3
- 6.99
- Shareholder net income q3
- 1365000000
- Cms risk adjustment accrual
- 935000000
- Benefit expense ratio change
- -70 bp
- Quarterly dividend per share
- 1.72
- Medical membership change yoy
- -487 thousand
- Buyback remaining authorization
- $5.0 billion
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.